New Data Further Validates use of Decipher Prostate in Men with Intermediate-Risk Prostate Cancer
Men with Intermediate-Risk Prostate Cancer Have a Variety of Treatment Options Available
Men with Intermediate-Risk Prostate Cancer Have a Variety of Treatment Options Available
Men diagnosed with NCCN favorable or unfavorable intermediate-risk prostate cancer are faced with a variety of treatment options, sometimes making it difficult to create an optimal plan of care.
Men Diagnosed with Favorable and Unfavorable Intermediate-Risk Prostate Cancer Have a Spectrum of Metastatic Risk
Men Diagnosed with Favorable and Unfavorable Intermediate-Risk Prostate Cancer Have a Spectrum of Metastatic Risk
Genomics can help further stratify these patients. Knowing more about the underlying biology of the patient's tumor can help personalize therapy.
According to the NCCN Guidelines® for Prostate Cancer, additional risk assessments may be considered to guide use of hormone therapy:
Favorable Intermediate-risk:
"Prophylactic lymph node radiation is not performed routinely, and ADT or antiandrogen therapy is not used routinely. Prophylactic lymph node radiation and/or ADT use is reasonable if additional risk assessments suggest aggressive tumor behavior."
Unfavorable Intermediate-risk:
"Prophylactic nodal radiation can be considered if additional risk assessments suggest aggressive tumor behavior. ADT should be used unless additional risk assessments suggest less-aggressive tumor behavior or if medically contraindicated. The duration of ADT can be reduced when combined with ERBT and duration of ADT can be reduced when combined with EBRT and brachytherapy. Brachytherapy combined with ADT (without EBRT), or SBRT combined with ADT can be considered if delivering longer courses of ERBT would present medical or social hardship."
New Data from Post-Hoc Analysis of RTOG 0126 Further Supports use of Decipher Prostate as a Biomarker for Intermediate-Risk Prostate Cancer
New Data from Post-Hoc Analysis of RTOG 0126 Further Supports use of Decipher Prostate as a Biomarker for Intermediate-Risk Prostate Cancer
Study: Data from a post-hoc analysis of a phase III randomized trial (NRG/RTOG 0126).
Cohort: 215 men with intermediate-risk prostate cancer randomized to treatment with 70.2 Gy vs 79.2 Gy without hormone therapy. 61% of patients were Gleason 3+4 and 24% of men were Gleason 4+3.
This study is the first validation of any genomic classifier in intermediate-risk prostate cancer using randomized phase III trial data.
Decipher was Independently Prognostic for all Outcomes Including Metastasis, Prostate Cancer Specific Mortality, Metastasis-free Survival and Overall Survival.
Decipher was Independently Prognostic for all Outcomes Including Metastasis, Prostate Cancer Specific Mortality, Metastasis-free Survival and Overall Survival.
- NCCN intermediate risk prostate cancer is the most heterogeneous of all risk groups in prostate cancer, and there is a wide variety of treatment options available. Decipher can help personalize treatment for patients diagnosed with intermediate-risk prostate cancer. Providing additional information about the aggressiveness of the tumor with the Decipher Prostate Genomic Classifier can help determine a better treatment path.
- Decipher high-risk men may have better outcomes with more intense treatment, while Decipher low-risk men have good outcomes with radiation alone.
Reference: Spratt et al., Validation of the performance of the Decipher Biopsy genomic classifier in intermediate-risk prostate cancer on the phase II randomized trial NRG Oncology/RTOG 0126. Journal of Clinical Oncology 2022 40:6_suppl, 269-269.
Decipher can help clinicians make decisions across a broad range of clinical scenarios.
Decipher can help clinicians make decisions across a broad range of clinical scenarios.
Decipher calculates a patient’s genomic risk without factoring in other clinical characteristics. This new and meaningful perspective provides greater clarity and confidence in determining the best treatment plan.